Indications
Each indication opens its study.
Stage of development
-
PNB-101
Lung CancerCCK-B pathway inhibition
- Molecule
- PNB-101
- Indication
- Lung Cancer
- Biological action
- CCK-B pathway inhibition
- Status
- IND ready
-
PNB-101
Liver CancerCCK-B pathway inhibition
- Molecule
- PNB-101
- Indication
- Liver Cancer
- Biological action
- CCK-B pathway inhibition
- Status
- IND ready
- Target and mechanism
- CCK-B (CCK2/gastrin) receptor blocker. Its chlorinated sister molecule, PNB-102, is suited to CNS applications.
- Key findings
In a xenograft study with the human Lung Cancer cell line NCI-H727, oral dosing inhibited tumour growth by more than 80% in responders after 28 days.
In the C38 murine lung cell line, in vitro anti-cancer activity exceeded that of the reference CCK2 antagonist CI-988.
- Development
Two-step synthesis from economical raw materials. ICH toxicology studies are scheduled to begin after PNB-081.
- Intellectual property
- Patents filed in the US, Europe and rest of world; PCT application filed and granted; USPTO patent issued 28 December 2014.
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
